- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
396 CHAPTER 8 Stone disease
Treatment options for ureteric stones
-ESWL: in situ; after push-back into the kidney (i.e., into the renal pelvis or calyces); or after JJ stent insertion
-Ureteroscopy
-PCNL
-Open ureterolithotomy
-Laparoscopic ureterolithotomy
Basketing of stones (blind or under radiographic control) are historical treatments (the potential for serious ureteric injury is significant).
The ureter can be divided into two halves (proximal and distal to the iliac vessels) or in thirds (upper third from the UPJ to the upper edge of the sacrum; middle third from the upper to the lower edge of the sacrum; lower third from the lower edge of the sacrum to the VUJ).
AUA guidelines panel recommendations1
These guidelines should be interpreted in light of the following:
-Recent (within the last 5 years or so) improvements in ureteroscope design
-Local facilities and expertise
Smaller ureteroscopes with improved optics and larger instrument channels and the advent of holmium laser lithotripsy have improved the efficacy of ureteroscopic stone fragmentation (to ~95% stone clearance) and reduced its morbidity. As a consequence, many surgeons and patients will opt for ureteroscopy, with its potential for a one-off treatment, over ESWL, which requires more than one treatment and post-treatment imaging is needed to confirm stone clearance (with ureteroscopy you can directly see that the stone has gone).
Most urology departments do not have unlimited access to ESWL and patients may therefore opt for ureteroscopic stone extraction.
The stone clearance rates for ESWL are stone-size dependent. ESWL is more efficient for stones <1 cm in diameter than for those >1 cm in size. Conversely, the outcome of ureteroscopy is somewhat less dependent on stone size.
Recommendations
Proximal ureteric stones
-<1 cm diameter: ESWL (in situ, push-back)
->1 cm diameter: ESWL, ureteroscopy, PCNL
JJ stent insertion does not increase stone-free rates and is therefore not required in routine cases. It is indicated for pain relief, relief of obstruction, and in those with solitary kidneys.
Distal ureteric stones
-Both ESWL and ureteroscopy are acceptable options.
-Stone-free rate <1 cm: 80–90% for both ESWL and ureteroscopy; >1 cm: 75% for both ESWL and ureteroscopy.
1 Segura JW, Preminger GM, Assimos DG, et al. (1997) Ureteral stones clinical guidelines panel summary report on the management of ureteral calculi. J Urol 158:1915–1921.
TREATMENT OPTIONS FOR URETERIC STONES 397
Failed initial ESWL is associated with a low success rate for subsequent ESWL. Therefore, if ESWL has no effect after one or two treatments, change tactics.2
Open ureterolithotomy and laparoscopic ureterolithotomy are used when ESWL or ureteroscopy have been tried and failed or were not feasible.
2 Pace KT. et al. (2000). Low success rate of repeat shock wave lithotripsy for uretal stones after failed initial treatment. J Urol 164:1905–1907.
398 CHAPTER 8 Stone disease
Prevention of calcium oxalate stone formation
A series of landmark papers from Harvard Medical School1 and other groups help us to give rational advice on reducing the risk of future stone formation in those who have formed one or more stones. The Harvard studies stratified risk of stone formation on the basis of intake of calcium and other nutrients (Nurses Health Study, n = 81,000 women; equivalent male study, n = 45,000).
Low fluid intake
Low fluid intake may be the single most important risk factor for recurrent stone formation. High fluid intake is protective,1 by reducing urinary saturation of calcium, oxalate, and urate.
Time to recurrent stone formation is prolonged from 2 to 3 years in previous stone formers randomized to high fluid vs. low fluid intake (averaging about 2.5 vs. 1 L/day) and over 5 years, risk of recurrent stones was 27% in low-volume controls compared with 12% in high-volume patients.2
Dietary calcium
Conventional teaching was that high calcium intake increases the risk of calcium oxalate stone disease. The Harvard Medical School studies have shown that low calcium intake is, paradoxically, associated with an increased risk of forming kidney stones, in both men and women (relative risk of stone formation for the highest quintile of dietary calcium intake vs. the lowest quintile = 0.65; 95% confidence intervals 0.5 to 0.83—i.e., high calcium intake was associated with a low risk of stone formation).
Calcium supplements
In the Harvard studies,3 the relative risk of stone formation in women on supplemental calcium compared with those not on calcium was 1.2 (95% confidence intervals 1.02–1.4). In 67% of women on supplements, the calcium was either not consumed with a meal or was consumed with a meal with low oxalate content. It is possible that consuming calcium supplements with a meal or with oxalate-containing foods could reduce this small risk of inducing kidney stones.
Other dietary risk factors related to stone formation
Increased risk of stone formation (relative risk of stone formation shown in brackets for highest to lowest quintiles of intake of particular dietary factor):
-Sucrose [1.5]
-Sodium [1.3]: high sodium intake (leading to natriuresis) causes hypercalciuria
-Potassium [0.65]
1 Curhan GC, et al. (1993). A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328:833–38.
2 Borghi L, et al. (1996). Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. J Urol 155:839–843.
3 Curhan G, et al. (1997). Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126:497–504.
PREVENTION OF CALCIUM OXALATE STONE FORMATION 399
Animal proteins
High intake of animal proteins causes increased urinary excretion of calcium, reduced pH, high urinary uric acid, and reduced urinary citrate, all of which predispose to stone formation.4
Alcohol
Curhan’s studies from Harvard5 suggest small quantities of wine decrease risk of stones.
Vegetarian diet
Vegetable proteins contain less of the amino acids phenylalanine, tyrosine, and tryptophan that increase the endogenous production of oxalate. A vegetarian diet may protect against the risk of stone formation.6,7
Dietary oxalate
A small increase in urinary oxalate concentration increases calcium oxalate supersaturation much more than an increase in urinary calcium concentration. Mild hyperoxaluria is one of the main factors leading to calcium stone formation.8
4 Kok DJ (1990). The effects of dietary excesses in animal protein and in sodium on the composition and crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab 71:861–867.
5 Curhan G, et al. (1998). Beverage use and risk for kidney stones in women. Ann Intern Med 128:534–540.
6 Robertson WG, et al. (1982). Prevalence of urinary stone disease in vegetarians. Eur Urol 8:334–339. 7 Borghi, L (2002). Comparison of two diets for prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346:77–84.
8 Robertson WG, Peacock M, Ouimet D, et al. (1981). The main risk for calcium oxalate stone disease in man: hypercalciuria or mild hyperoxaluria? In Smith LH, Robertson WG, Finlayson B (Eds.), Urolithiasis: Clinical and Basic Research. New York: Plenum Press, pp. 3–12.